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Background: Beta lactams are the most commonly used group of antimicrobials worldwide.
The presence of extended-spectrum lactamases (ESBL) affects significantly the treatment of infections due to
multidrug resistant strains of gram-negative bacilli. The aim of this study was to characterize the beta-lactamase
resistance genes in Escherichia coli isolated from nosocomial infections in Cotonou, Benin.
Methods: Escherichia coli strains were isolated from various biological samples such as urine, pus, vaginal swab,
sperm, blood, spinal fluid and catheter. Isolated bacteria were submitted to eleven usual antibiotics, using disc
diffusion method according to NCCLS criteria, for resistance analysis. Beta-lactamase production was determined by
an acidimetric method with benzylpenicillin. Microbiological characterization of ESBL enzymes was done by double
disc synergy test and the resistance genes TEM and SHV were screened by specific PCR.
Results: ESBL phenotype was detected in 29 isolates (35.5%). The most active antibiotic was imipenem (96.4% as
susceptibility rate) followed by ceftriaxone (58.3%) and gentamicin (54.8%). High resistance rates were observed
with amoxicillin (92.8%), ampicillin (94%) and trimethoprim/sulfamethoxazole (85.7%). The genotype TEM was
predominant in ESBL and non ESBL isolates with respectively 72.4% and 80%. SHV-type beta-lactamase genes
occurred in 24.1% ESBL strains and in 18.1% of non ESBL isolates.
Conclusion: This study revealed the presence of ESBL producing Eschericiha coli in Cotonou. It demonstrated also
high resistance rate to antibiotics commonly used for infections treatment. Continuous monitoring and judicious
antibiotic usage are required.
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Antibiotics resistance is a paramount issue in medical
practice. Production of β-lactamases is an important
means by which Gram-negative bacteria exhibit resistance
to β-lactam antibiotics [1]. The increasing prevalence
of pathogens producing extended-spectrum-lactamases
(ESBLs) is showed worldwide in hospitalized patients as
well as in out-patients. Infections with ESBL producing* Correspondence: anagocina@yahoo.com
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unless otherwise stated.organisms are associated with higher rates of mortality,
morbidity and healthcare expenditure. ESBLs are often
plasmid mediated; though they occur predominantly in
Escherichia coli and Klebsiella species, they have also been
described in other genera of the Enterobacteriacea [1,2].
Multidrug resistance in ESBL producers limit therapeutic
options and subsequently facilitate the dissemination of
these bacteria strains. Several studies have reported the in-
creasing resistance rate of commonly prescribed antibiotics
such as ampicillin, trimethoprim/sulfamethoxazole and
ciprofloxacin in clinical isolates of Escherichia coli [3-6].
Antibiotic resistance varies according to geographic lo-
cations and is directly proportional to the use and misuse
of antibiotics. Understanding the effect of drug resistanceThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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infections. In Benin, little information about resistance to
third generation cephalosporin as well as multi drug re-
sistance in Escherichia coli is known. As antibiotic treat-
ment must rely on antimicrobial susceptible pattern,
current knowledge on susceptibility is essential for appro-
priate therapy. Previous studies reported the presence of
TEM and SHV in nosocomial and community isolated
Escherichia coli strains in Benin [7,8].
The aim of the present study was to characterize
clinical isolates of Escherichia coli obtained from sev-
eral infections in Cotonou in order to (i) determine the
susceptibility patterns to antibiotics, (ii) evaluate the
prevalence of ESBL and (iii) identify the genes involved
in the resistance.Materials and methods
Bacterial strains
The study was carried out in three hospitals in Cotonou,
from September 2012 to April 2013. Consecutive, non-
repeated nosocomial Escherichia coli isolates obtained
from urine, pus, vaginal swab, sperm, blood, spinal fluid
and catheter samples received in the bacteriology la-
boratories were analyzed. The isolated microorganisms
were considered as nosocomial origin if they were isolated
from patients admitted to the hospitals since 48 hours or
more. The main pathogens were identified by cultural
characteristics and standard biochemical procedures and
were confirmed with API 20 E (Biomérieux, Marcy l’Etoile,
France) identification system.Antibiotic susceptibility testing and detection of ESBL
Antibiotic susceptibility was performed by the disc diffu-
sion method on Mueller Hinton agar (Bio-Rad, Marne la
Coquette, France) according to the recommendations of
the Antibiogram Committee of the French Society for
Microbiology (Comité de l’Antibiogramme de la Société
Française de Microbiologie) [9]. The following antibiotic
discs (drug concentration in μg) were tested: amoxicillin
(25 μg), amoxicillin/clavulanic acid (20/10 μg), ampicillin
(10 μg), imipenem (10 μg), cefotaxime (30 μg), ceftriaxone
(30 μg), ciprofloxacin (5 μg), norfloxacin (5 μg), amikacin
(30 μg), gentamicin (15 μg) and trimethoprim/ sulfameth-
oxazole (1.25/23.75 μg), all from Bio-Rad (Bio-Rad, Marne
la Coquette, France).
ESBL phenotypes were detected by double-disk synergy
according to the method described by Jarlier et al. [10].
Disks of cefotaxime and ceftriaxone were placed 20 mm
from an amoxicillin/clavulanate disk. Enhancement of
the inhibition zone of the third-generation cephalo-
sporin toward the amoxicillin/clavulanate disk indicated
the possible presence of an ESBL. Escherichia coli ATCC
25922 was used as control.Biochemical detection of beta-lactamase production
The presence of beta-lactamase was tested by an acidi-
metric method using benzylpenicillin as substrate [11].
A single colony was resuspended and mixed with the
indicator solution. The indicator solution was prepared
by adding 1 ml of sterile distilled water and 100 μl of
1% phenol red solution to a vial of one million units
of sodium benzylpenicillin (Crystapen, Glaxo). A solu-
tion of 1 N sodium hydroxide was added until the de-
velopment of violet color (pH 8.5). Several colonies
were suspended in NaCl, 9‰ to get a dense suspen-
sion. 150 μl of penicillin phenol red solution was
added and the color development observed within 1
hour. The solution turned yellow in the presence of
beta-lactamase.
Detection of beta-lactamase genes
All the strains were further analyzed by PCR to detect
beta-lactamase genes. Total DNA extraction was per-
formed using the heat-shock method. Briefly, a single bac-
teria colony was inoculated into 5 ml of Luria-Bertani
broth (Biorad, Marne la Coquette, France) and incubated
for 20 h at 37°C. Cells from 1.5 ml of the overnight culture
were harvested by centrifugation at 7000 RPM for 5 min.
After the supernatant was removed, the pellet was washed
twice with sterile water and resuspended in 500 μl of ster-
ile water. This suspension was incubated at 95°C during
10 min. The supernatant was stored at −20°C for PCR
analysis.
The presence of beta-lactamase genes, blaTEM and
blaSHV, was detected using specific primers: for the TEM
genes OT-1-F [5′-TTGGGTGCACGAGTGGG TTA-3′]
and OT-2-R [5′-TAATTGTTGCCGGGAAGCTA-3′]
which amplified a 465 bp fragment [12]; for the SHV
genes, SHV-A[5′-CACTCAAGGATGTATTGTG-3′] and
SHV-B[5′-TTAGCGTTGCCAGTGCTCG-3′] which amp-
lified a fragment of 885 bp [13].
Amplification reactions were performed in a volume
of 30 μl containing 4 μl of supernatant, (volume)
PCR buffer (1x), MgCl2 (1.5 mM), (volume) dNTPs
(200 μM), (volume) primer (0.5 mM), 0.2 μL of Taq
DNA polymerase (1,5U). An Biometra thermal cycler
was used for the amplification. The cycling conditions
were the following:
TEM: initial denaturation at 94°C for 5 min, followed
by 30 cycles of denaturation at 94°C for 30 s, annealing
at 52°C for 30 s , extension at 72°C for 1 min;
SHV: initial denaturation at 96°C for 15 s, followed by
30 cycles of denaturation at 96°C for 15 s, annealing at
50°C for 15 s, extension at 72°C for 2 min. Both PCR pro-
grams were followed by a final extension step of 10 min.
Amplified PCR products were separated on 1.5% agar-
ose gels, stained with ethidium bromide and visualized
under UV illumination.
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Data were analyzed with Epi Info® version 3.5.4. Differ-
ences in antibiotic susceptibility among different groups
were statistically analyzed by the Fisher exact test. An
associated P-value < 0.05 was considered significant.
Results
A total of 84 nosocomial Escherichia coli isolates were
included in this study. The majority of isolates (72 strains:
85.7%) were from urine samples. Specimens from pus rep-
resented 4.76% of the isolates, followed by vagina swab
and spinal liquid with 2.38% each. Isolates from sperm
and catheter were 1.2% each.
The antibiotics susceptibility test revealed that the most
efficient antibiotics were imipenem (96.4% as susceptibility
rate) followed by ceftriaxone (58.3%) and gentamicin
(54.8%). High resistance rates were observed with amoxi-
cillin (92.8%), ampicillin (94%), and trimethoprim/sulfa-
methoxazole (85.7%). Resistance to amoxicillin/clavulanic
acid was 85.7% with a high rate of intermediate resistance
(46.7%). We observed homogeneity in the resistance pro-
file of ESBL-producers which were multi drugs resistant
with at least a resistance to 8 antibiotics out of the 11
tested (Table 1).
According to the biochemical detection of beta-lactamase
production, 87.0% of isolates were positive using the acidi-
metric test by hydrolyzing penicillin G.
Of the 84 isolates screened for ESBL production by
the double disk test, 29 (35.5%) were positive using ei-
ther cefotaxime or ceftriaxone. Among these ESBL-
producers, 21 were from urinary tract infection (UTI)
and 8 from other infection sites. The other infection
sites seem to be disproportionally represented than
UTI (27.6% versus 14%). This fact could be explainedTable 1 Antibiotic susceptibility pattern of ESBL and non ESB













*P value is for the comparison of resistance of ESBL-producers with non-producers.
AM: Ampicilline; AMC: Amoxicilline/clavulanic acid; AMX: Amoxicilline; IPM: Imipene
AN: Amikacine; G: Gentamicine; SXT: Trimethoprim/Sulfamethoxazole.with reduced number of samples drawn from non-
urinary infections.
Comparison of susceptibility rates of ESBL producers
with those of ESBL non producers showed similar values
for amoxicillin, ampicillin and imipenem. No statistically
significant difference between the two groups was observed
(Table 1). For all other tested antibiotics, ESBL strains were
more resistant than non ESBL strains.
According to the PCR, the genotypes TEM and SHV
were distributed as follow: blaTEM 65 (77.4%) and blaSHV
17 (20.2%). These genotypes occurred singularly in 54
isolates (64.3%) with 51(94.4%) for blaTEM and 3 (5.6%)
for blaSHV. Both TEM and SHV genes were present in 14
isolates (16.7%) and absent in 16 isolates (19%) including
10 non ESBL strains and 6 ESBL strains.
Out of the 29 isolates with ESBL phenotype, the PCR
analysis revealed 72.4% strains with the genotype TEM,
24.1% with the genotype SHV and 5 strains harbored
both genes. Figure 1 showed the agarose gel of PCR
products following amplification of SHV genes.
As shown in Table 2, there were no difference in re-
sistance rate against ceftriaxone and cefotaxime. No dif-
ference was found between the inhibition diameters of
both antibiotics regarding the genotypes TEM and SHV.
Discussion
Our study was carried out in three hospitals in Cotonou,
Benin. Of the 84 isolates tested, 72 (85.7%) were from
urinary tract infections (UTI). This finding is similar to
results previously described by several studies [7,14-16].
This was expected since clinical isolates of Escherichia
coli were predominantly responsible of UTI [17,18].
The highest susceptibility of E. coli isolates was found
to imipenem (96.4%). In 2007 we have showed that theL producing isolates
ESBL (n = 29) Non-ESBL (n = 55) p-value*
29 (100%) 50 (91 %) 0.4
24 (82.7%) 15 (27.3%) 10−4
29 (100%) 49 (89.1%) 0.17
01 (3.4%) 00 (0%) 0.3
28 (96.5%) 01 (1.8%) <10−9
28 (96.5%) 01 (1.8%) 10−3
29 (100%) 14 (25.5%) 10−10
28 (96.5%) 14 (25.5%) <10−9
21(72.4%) 19 (34.5%) 0.04
24 (82.7) 12 (21.8) 10−7
29 (100%) 43 (78.2%) 6.10−3




Figure 1 Agarose gel of PCR products following amplification of SHV genes. M: Molecular weight marker; Lanes 02 to 08: SHV positive
samples; T0: negative probe without DNA.
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and 2% in non ESBL isolates [7]. A similar high sensibility
(93%) was observed by Muvunyi et al. in Rwanda [19].
Studies conducted in Iran [20], Morocco [21] and Nigeria
[22] reported almost high sensibility of E. coli isolates to
imipenem at rates of 98.4%, 96.7% and 92.5% respectively.
This finding may be due to the stability and the high activ-
ity of carbapenem against most beta-lactamases.
High resistance rates were founded to commonly used
antibiotics in Benin such as ampicillin (97.6%), amoxicil-
lin (95.2%) and trimethoprim/sulfamethoxazole (86.9%).
The observed high rates may be due to uncontrolled
consumption, consequence of easy access to inefficient
and cheap antibiotics.
Among the tested fluoroquinolones, only 8.3% of the
isolates were sensitive to ciprofloxacin. Norfloxacin was
more efficient with 44.6% of sensitive strains, but lower
than the result reported by Thakur et al. [6] with 52.5%
of sensitivity. Previous studies in Benin reported lower
resistance rates of ciprofloxacin compared to our study.
Ahoyo et al. reported 48% and 16% resistance to cipro-
floxacin in ESBL and non ESBL E. coli from nosocomial
infections, respectively [7]. Our survey realized in 2004
showed resistance rate of 18% in ESBL producers and
14% in non ESBL isolates from community acquiredTable 2 Association between ESBL genotype and antibiotic se
Genotypes Presence Cefotaxime ceftriaxon
S
TEM + 0 (0%)
- 0 (0%)
SHV + 0 (0%)
- 0 (0%)
TEM + SHV + 0 (0%)
- 0 (0%)
S = sensitive; I = intermediate; R = resistant. + indicate the presence of the genotypeUTI [8]. The higher rate of resistance to ciprofloxacin in
the current study could be explained by intensive use of
ciprofloxacin in the past decade.
Lower resistance rates to ciprofloxacin, usually pre-
scribed in uncomplicated UTI and other infections, have
been reported in Nepal (45%) [6], in India (52.80%) [23]
and in Iran (60%) [20]. It was showed that uncontrolled
use of quinolones in the past years led to a growing re-
sistance to these antibiotics particularly to ciprofloxacin
worldwide [24,25]. The use of ciprofloxacin selected also
ESBL producers due to the widespread co-detection of
both resistance mechanisms [26,27].
High resistance rate to amoxicillin/clavulanate acid
was also observed (85.7%). This finding is in agreement
with previous investigations in Benin. In 2007, we re-
ported resistance rates of 97.5% in ESBL and 53% in non
ESBL E. coli strains from nosocomial infections [7]. In
our previous study performed in 2004, we detected 72%
of resistance in ESBL and 9% in non ESBL E. coli isolates
from out-patients [8].
We showed in this study that 87% of isolated strains
were positive for beta-lactamase detection by acidimetric
method indicating that the most important mechanism
of resistance to beta-lactam antibiotics is the production
of beta-lactamase.nsibility profile
e n (%) Fisher’s exact test
I R p-value
0 (0%) 21 (100%) 0.27
1 (12.5%) 7 (87.5%)
0 (0%) 7 (100%) 0.76
1 (4.5%) 21 (95.5%)
0 (0%) 5 (100%) 0.54
1 (16.7%) 5 (83.3%)
. – indicate the absence of the genotype.
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was similar to those generally shown in developing
countries.
Our finding is very close to the prevalence ESBL re-
ported in India (35.45%) [28] and similar to the preva-
lence in Tanzania (39.1%) [29]. Previous studies in Benin
revealed relative high prevalence rates of ESBL produ-
cing E. coli. In 2007, Ahoyo et al. showed a prevalence
of 22% in isolates from various nosocomial infections. In
2004, we founded that 14.8% of E. coli strains isolated
from urinary tract infection (UTI) were ESBL [8]. Lower
ESBL prevalence was described in Morocco (1.3%) in
UTI isolated strains [30], in Cameroon (16%) in strains
isolated from feces in the community [25].
Among the ESBL-producers, the other infection sites
seem to be disproportionally represented than UTI (27.6%
versus 14%). This fact could be explained with a small
number of samples drawn from non-urinary infections.
The comparison between ESBL producing strains and
non ESBL showed that ESBL-producers were significantly
more resistant to cephalosporins, quinolones, aminosides,
trimethoprim/sulfamethoxazole and amoxicillin/clavulanic
acid than non-ESBL producers. The genes encoding ESBLs
are usually located in transferable plasmids that may also
carry other resistance determinants, such as those for re-
sistance to aminoglycosides, tetracyclines, chloramphenicol,
trimethoprim, sulphamides, and quinolones [31,32].
The genotype TEM was predominant in ESBL and non
ESBL isolates with respectively 72,4% and 80%. This fact
was generally observed in E. coli. The remaining 6 ESBL
strains which were non TEM and non SHV could harbor
CTX-M genes. Widespread dissemination of these genes
has been described in Africa and elsewhere [14,25,31].
Out of the 65 strains harboring TEM genes, 59 showed
positive result for the detection of enzyme production
using hydrolysis of penicillin. Of the 17 SHV positive
strains, 15 (80.95%) were positive for this test.
In this study, the phenotypic screening for ESBL was real-
ized by resistance to cefotaxime or ceftriaxone. The presence
of genotype TEM and SHV could not predict the resistance
pattern to these cephalosporins. Our finding is consistent
with the results reported by Maina et al. who found no
significant association between genotypes TEM and SHV
and susceptibility to cefotaxime and ceftriaxone [33].
Conclusions
This study reveals the presence of ESBL producing
Escherichia coli in clinical isolates from several hospi-
tals in Cotonou. The use of some first line treatment
antibiotics such as penicillin and trimethoprim/sulfa-
methoxazole seems inappropriate. Antibiotics resistance
surveillance and the determination of molecular charac-
teristics of ESBL isolates are primordial to ensure the judi-
cious use of antimicrobial drugs.Competing interests
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